Don’t miss the latest developments in business and finance.

Abbott beats Street on strong medical device, generics sales

Image
Reuters
Last Updated : Oct 18 2017 | 7:22 PM IST

(Reuters) - Abbott Laboratories' profit and sales topped analysts' estimates on robust sales of medical devices and generic drugs, leading it to raise the high-end of its adjusted earnings forecast for the year.

Abbott had a string of medical device approvals in the quarter that will spur future growth at its largest unit, which saw sales rise 6.5 percent to $2.60 billion. The company also benefited from the recent St. Jude Medical acquisition.

"Strength in medical devices pulled this quarter ... recent product approvals puts Abbott in a good position," Raj Denhoy from Jefferies told Reuters.

Sales at the diversified healthcare company's established generics unit, which surged 16 percent, also helped the quarter.

Abbott forecast full-year adjusted 2017 profit from continuing operations of $2.48-$2.50 per share. It had earlier expected earnings per share of $2.43-$2.53.

The company's shares were trading marginally up at $55.45 before the bell on Wednesday.

Also Read

Several devices received U.S. Food and Drug Administration approvals in the quarter, including Abbott's FreeStyle Libre glucose monitoring system and two of its heart devices - HeartMate 3 and Ellipse.

Excluding items, profit was 66 cents per share. Net sales rose to $6.83 billion from $5.30 billion.

Analysts on average expected earnings of 65 cents per share, on revenue of $6.72 billion, according to Thomson Reuters I/B/E/S.

Net earnings rose to $603 million, or 34 cents per share, in the third quarter ended Sept. 30, from a loss of $329 million, or 22 cents per share, a year earlier, when it recorded a charge.

(Reporting by Manas Mishra and Akankshita Mukhopadhyay in Bengaluru; Editing by Martina D'Couto)

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Oct 18 2017 | 7:05 PM IST

Next Story